Application of FIT-DNA Detection in Following Colorectal Cancer Resection-Implications for Surveillance

NCT ID: NCT05528783

Last Updated: 2022-09-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-04-25

Study Completion Date

2027-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Colorectal cancer (CRC) is a common cancer that threatens human health, with the incidence ranking the third in the world. 70% of patients are in the middle and late stages whendiagnosed, and even after radical surgery, 30% - 50% of patients with CRC have recurrence or metastasis after radical surgery. Therefore, after radical surgery and adjuvant chemotherapy, regular monitoring of CRC patients should be paid attention to in order to detect the recurrence and metastasis lesions that can be resected and the early non-invasive metachronous multiple primary tumors.

The sensitivity of FIT-DNA to CRC was 95.5%, the sensitivity to advanced adenoma (AA) was 63.5%, and the specificity was 87.5%, showing a good ability to screen colorectal cancer and precancerous lesions.

At present, there is no report on the application of FIT-DNA combined detection technology in the high-risk recurrence period and mid - and long-term monitoring after CRC surgery in China. In this study, Fit-DNA combined detection technology was applied to the follow-up monitoring of patients after CRC surgery, so as to optimize the current typical postoperative follow-up strategy, find early recurrence and multiple primary colorectal tumors after CRC surgery, seek the best postoperative follow-up model, improve the compliance of patients to follow-up, and ultimately benefit survival.

Detailed Description:Outline:This study was a single-center, observational study. Fit-DNA detection technology was used as a target method, and colonoscopy was used as the gold standard control to follow up and monitor patients with colorectal tumors after surgery, and to explore whether it is an effective non-invasive auxiliary method for monitoring CRC recurrence and metastasis and multiple primary colorectal tumors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1). The pathological diagnosis was colorectal adenocarcinoma; 2). Age: 18 to 80 years old,allgenders; 3). Radical surgery for CRC is required; 4). No preoperative antitumor therapy (including chemotherapy, radiation therapy, targeted therapy, and immunotherapy); 5). Preoperative examination revealed no distant metastasis; 6). There were no severe hemorrhoids or other known conditions that can cause gastrointestinal bleeding before surgery; 7). The clinical treatment data were complete;

Exclusion Criteria

* 1). With a history of digestive tract tumors other than CRC; 2). Previous colorectal surgery; 3). Patients requiring a fistula; 4). With complete intestinal obstruction or perforation; 5). Women who are pregnant or breastfeeding; 6). Patients with metastases found in other sites during surgery that cannot be removed radically; 7). Patients unwilling or unable to sign an informed consent form; 8). A strict vegetarian; 9). Patients who are unwilling to follow up according to the protocol or have poor follow-up compliance; 10). Any conditions that the study physician deemed inappropriate for inclusion。

Exit or terminate criteria:

1. . Follow-up information for the patients was not available
2. . Distant metastasis was diagnosed after surgery
3. . Subjects died before the end of follow-up.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

New Horizon Health

UNKNOWN

Sponsor Role collaborator

Sun Yat-sen University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

ZHI-ZHONG PAN

Professor, Director, M.D., Ph.D

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Colorectal Department,SunYat-sen University Cancer Center

Guangzhou, Guangdong, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Junzhong Lin

Role: CONTACT

+86-13802446666

Zhizhong Pan

Role: CONTACT

+86-13719388166

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Junzhong lin, PhD

Role: primary

+86-13802446666

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-AFFCCR

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.